Skip to content Skip to footer

International Cannabis Weekly: 273

November 11, 2022

Highlights

Share this story

NEW YORK ON TRACK TO OPEN FIRST ADULT-USE CANNABIS STORES BY END OF 2022

The first New York recreational marijuana retailer licenses could be approved in about two weeks, a top regulator said on Thursday 3 November, at Business of Cannabis: New York conference, previewing plans for an upcoming Cannabis Control Board (CCB) meeting.

While nothing has been formally scheduled and announced yet, CCB is expected to meet on November 21 and potentially approve the first set of Conditional Adult Use Retail Dispensary (CAURD) licenses, Axel Bernabe of the Office of Cannabis Management (OCM) said at the Business of Cannabis conference in New York City.

READ MORE »

CANTOURAGE: FIRST MEDICAL CANNABIS FIRM TO LIST ON THE FRANKFURT STOCK EXCHANGE

READ MORE »

RESULTS FROM MIDTERM CANNABIS LEGALISATION MEASURES ARE IN

READ MORE »

Highlights

Share this story
Europe
  • A dozen German Cannabis Social Clubs have founded an organisation to help people grow their own cannabis plants.
  • Portugal’s first cannabis manufacturing company ATANN has successfully been granted its GACP licence.
  • Thousands of CBD products in the UK are expected to be validated by the FSA in the coming weeks.
  • An Isle of Man pharmacy is due to begin a medical cannabis dispensing trial next month.
  • High Court test case against zero-tolerance cannabis policy in Ireland has been refused.
  • Switzerland could become the second European country to legalise adult-use cannabis, following Germany.
  • Akanda’s first shipment to Germany of high-THC premium cannabis has arrived from its Portugal-based operation.
  • Leva Clinic has secured £3m of funding to accelerate innovation that could transform treatments for UK pain patients.
  • Clever Leaves has been granted EU-GMP certification by the Portuguese Health Authority.
  • Cannabis could be fully-legalised in the Czech Republic next year, with the planning process already in motion.
  • Patients share their perspectives on medical cannabis at the UK’s first patient conference in London.

Highlights

Share this story
Stocks

Highlights

Share this story
United States

Highlights

Share this story
Canada
  • Canopy Growth Corporation reports second quarter fiscal year 2023 financial results, with 7% revenue growth.
  • Juva Life has started construction on its Californian retail location, expected to open early 2023.
  • Nova Cannabis has announced its third quarter 2022 financial results, with a 4.6% revenue increase.
  • Repeat cross-sectional study shows consumer perceptions of legal cannabis products in Canada 2019-2021.
  • Village Farms International has announced financial results for the third quarter of 2022 financial year.
  • Delta 9 announces it has entered into an agreement with Kindred Partners to provide exclusive brokerage services.
  • More retail dispensaries adjacent to existing Circle K stores to be opened by Fire & Flower.

Highlights

Share this story
New Report

Highlights

Share this story
LATAM & The Caribbean
  • Adult-use cannabis legalisation in Colombia could go ahead, following the vote of support.
  • Seven million Peruvians could benefit from the properties of medicinal cannabis, according to a recent study.
  • Patients in Peru will have access to medical cannabis from Clever Leaves following its recent partnership.
  • Chamber of Sorocaba in Brazil debates on the rights of patients to use national or imported cannabis-based medicines.
  • The current changes in the Brazilian political arena and CFM controversy give strength to cannabis events.
  • The first licence for the cultivation and exportation of industrial hemp in Costa Rica has been granted.

Highlights

Share this story
APAC

Highlights

Share this story
Upcoming Event

Highlights

Share this story
Africa & The Middle East
Latest Issues

275

274

273

272

271

270

Insights

on the global cannabis industry

International Cannabis Weekly newsletter brings you the most important developments, news and informed commentary on the global cannabis industry. Join our community of 80,000+ subscribers.